Ifebemtinib

• CAT Number: I004226
• CAS Number: 1227948-82-4
• Molecular Formula: C28H28F4N6O4
• Molecular Weight: 588.55
• Purity: ≥95%
• Synonyms: 2-fluoro-5-methoxy-4-[[4-[(2-methyl-3-oxo-1H-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-N-(1-methylpiperidin-4-yl)benzamide
• InChI: InChI=1S/C28H28F4N6O4/c1-37-9-7-16(8-10-37)34-24(39)17-11-22(41-3)20(12-19(17)29)35-27-33-13-18(28(30,31)32)25(36-27)42-21-6-4-5-15-14-38(2)26(40)23(15)21/h4-6,11-13,16H,7-10,14H2,1-3H3,(H,34,39)(H,33,35,36)
• InChIKey: ULMMVBPTWVRPSI-UHFFFAOYSA-N
• SMILES: CN1CCC(CC1)NC(=O)C2=CC(=C(C=C2F)NC3=NC=C(C(=N3)OC4=CC=CC5=C4C(=O)N(C5)C)C(F)(F)F)OC

Ifebemtinib（Cat No.:I004226）is a selective small molecule inhibitor targeting the Bruton’s tyrosine kinase (BTK), an enzyme crucial for B-cell receptor signaling and immune cell activation. By inhibiting BTK, Ifebemtinib suppresses the activation of B-cells, which are involved in the pathogenesis of autoimmune diseases and certain cancers. It has shown promise in the treatment of conditions like rheumatoid arthritis and B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Ongoing clinical trials are investigating its safety, efficacy, and potential as a therapeutic option for immune-related diseases and hematologic cancers.